mybrca i mybrca HiRisk

Similar documents
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

Germline Testing for Hereditary Cancer with Multigene Panel

BRCAplus. genetic testing for hereditary breast cancer

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

Learn your genetic risk for the most common hereditary cancers.

Genetic testing and pancreatic disease

GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18

Multigene Panel Testing for Hereditary Cancer Risk

The Next Generation of Hereditary Cancer Testing

OvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer

Myriad Financial Assistance Program (MFAP)

Breast Cancer. Breast Tissue

patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center

Otkazivanje rada bubrega

Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool

The Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine

A guide to genetic testing for hereditary cancers

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.

Genetic testing for hereditary cancer

Germline Genetic Testing for Breast Cancer Risk

Enabling Personalized

Kidney Failure. Kidney. Kidney. Ureters. Bladder. Ureters. Vagina. Urethra. Bladder. Urethra. Penis

Genetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

Why Test for Hereditary Cancer in Preventive Care?

Uloga obiteljskog liječnika u prepoznavanju bolesnika s neuroendokrinim tumorom

Hereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com

Hereditary Cancer Products

Genetics and Cancer Care. Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer

Genetic Risk Assessment for Cancer

Clinical Cancer Genetics

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

Genetic Risk Assessment for Cancer

Genetic Testing: who, what, why?

Genetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017

Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017

Genetic Testing for BRCA1 and BRCA2 Genes

The Role of genetic Testing for Inherited Prostate Cancer Risk

Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep

REPUBLIKA ZDRAVA KRALJEŽNICA REPUBLIC OF HEALTHY SPINE PUTOVNICA PASSPORT

Corporate Medical Policy

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Genetic Testing for BRCA1 and BRCA2 Genes

Genetics & Precision Medicine Cancer Care

TumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in

Objectives. Genetics in Cancer Treatment and Prevention. Genes

RECOMMENDATIONS FOR HISTOPATHOLOGY REPORT OF COLORECTAL CARCINOMA SPECIMENS

Stroke Signs Your Care Call 911 as soon as you have any signs of a stroke.

DNA Genetic Cancer Risk Test. Test Report

Genetic counseling and testing. Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel

CASE STUDY. Germline Cancer Testing in A Proband: Extension of Benefits to Unaffected Family Members. Introduction. Patient Profile.

Talasemija - vrste, uzroci, simptomi i liječenje

MOLECULAR SERVICES. mlabs.umich.edu

MSI positive MSI negative

Hereditary Gastric Cancer

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Are you at risk of Hereditary Cancer? Your Guide to the Answers

Medical Policy Update

10/21/ New Release, Quest Diagnostics Nichols Institute, Valencia

Diagnostic and Treatment of Patients with Primary and Metastatic Breast Cancer

The Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno

Starting an Exercise Program

Informacioni sistemi i baze podataka

Populations Interventions Comparators Outcomes Individuals: With a personal and/or family history suggesting an inherited cancer syndrome

Genetic Panel Testing and Implications for Cancer Care

Genetic Determinants, Risk Assessment and Management

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention

Targeted therapy & Tumor molecular profile. Anton Tikhonov V Bioinformatics Summer School, 2017

GENETIKA KARCINOMA KOLONA GENETICS OF COLON CANCER

Understanding Your Positive Result. A guide to understanding your risk and taking action

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.

Dr. sc. Sendi Kuret, mol.biol. Klinički zavod za patologiju, sudsku medicinu i citologiju KBC Split Split,

NOVI MODALITETI U LIJEČENJU KARCINOMA DOJKE: GDJE SMO SAD?

PREVENCIJA I RANO OTKRIVANJE KARCINOMA DEBELOG CRIJEVA

Robert Nathan Slotnick MD PhD FACOG FACMG (FF) Perinatologist and Director Medical Genetics

Imunoterapija u liječenju karcinoma bubrega. AUTOR: Milena Gnjidić

A pathogenic mutation was identified in the BRCA1 gene.

Versus. Cancer genomics Competitive Analysis

Plasma-Seq conducted with blood from male individuals without cancer.

COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014

A HARD RAIN'S A-GONNA FALL: TEACHING STATISTICS FOR THE SOCIAL SCIENCES. Tanja Jevremov & Petar Milin University of Novi Sad

ריבוי פוליפים בחולה צעיר. איתי מזאה MD PhD

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

TGL clinical User Guide

Use of panel tests in place of single gene tests in the cancer genetics clinic

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

OVERACTIVE BLADDER AND URGENCY PREAKTIVNI MJEHUR I HITNOST

Transcription:

mybrca i mybrca HiRisk Jednostavnim screening testom na vrijeme mogu otkiti genetsku predispoziciju za razvoj karcinoma dojke, jajnika kao i drugih karcinoma. Želim živjeti bezbrižno! www.genetskitestovi.com

mybrca i mybrca HiRisk su jednostavni testovi iz uzorka sline koji otkrivaju mutacije na BRCA genima. ZAŠTO JE VAŽNO TESTIRATI SE? mybrca test određuje prisustvo mutacija na BRCA1 i BRCA2 genima dok mybrca HiRisk test određuje mutacije na 26 gena uključujući i BRCA1 i BRCA2 gene. BRCA geni su dio obrambenog sustava DNK Vašeg organizma. Procesom regulacije rasta i diobe stanica, popravljajući nepravilno stvorene DNK lance, BRCA geni sprječavaju razvoj zloćudnih tumora. Ukoliko ste nosioc BRCA gena koji ne funkcioniraju adekvatno (nosioci su štetne mutacije) Vaš rizik od razvijanja karcinoma dojke, jajnika i drugih karcinoma značajno se povećava*. * Povećanom riziku za razvoj karcinoma podjednako su podložni i žene i muškarci RIZIK ZA RAZVOJ KARCINOMA DOJKE TIJEKOM ŽIVOTA* RIZIK ZA RAZVOJ KARCINOMA JAJNIKA TIJEKOM ŽIVOTA* 12% 1.3% RIZIK ZA OPĆU POPULACIJU RIZIK ZA OPĆU POPULACIJU 80% 40% RIZIK S BRCA MUTACIJAMA RIZIK S BRCA MUTACIJAMA *Pogledajte veritasgenetics.com za reference. svakih 19 sekundi u svijetu se otkrije novi slučaj karcinoma dojke

mybrca test je kombinacija prevencije, ranog otkrivanja i liječenja TESTOVI ANALIZIRAJU MUTACIJE NA SLJEDEĆIM GENIMA Geni koji se analiziraju mybrca mybrca HiRisk BRCA 1 BRCA 2 ATM, BLM, BARD 1, BRIP 1, CDH 1, CHEK2, EPCAM, FAM 175A, MEN 1, MLH 1, MRE 11A, MSH 2, MSH 6, MUTYH, NBN, PALB 2, PMS 2, PTEN, RAD 50, RAD 51C, RAD 51D, STK 11, TP 53, XRCC2 Cijena 490 eura 590 eura TIPOVI KARCINOMA koji su povezani s mutacijom navedenih gena Karcinom debelog crijeva Karcinom endometrija Karcinom prostate Melanom Karcinom gušterače Karcinom želuca Ostali karcinomi SINDROMI NASLJEDNIH KARCINOMA koji su povezani s mutacijom navedenih gena Cowden sindrom Li-Fraumeni sindrom Peutz-Jeghers sindrom Lynch syndrom KAKO NAPRAVITI TEST? 1. Kontaktirajte nas kako biste naručili test i preuzeli set za uzimanje uzorka, 2. Uzorak sline prikupit ćete prema priloženim uputama, 3. Uzorak šaljemo na obradu i analizu u CLIA certificirani laboratorij Veritas Genetics-a u SAD 4. Rezultati će Vam biti dostupni za 4 do 6 tjedana

Neka Vaše odluke nadmudre Vaše gene REZULTATI TESTA* 1. Mutacija je detektirana, 2. Mutacija nije detektirana, 3. Prisustvo mutacije nepoznatog podrijetla **. * Svaki rezultat negativan ili pozitivan trebao bi biti dio načina procjene Vašeg zdravstvenog stanja i eventualnih terapijskih potreba ** Mutacije nepoznatog podrijetla su one za koje nije dokazano mogu li izazvati razvoj bolesti ŠTO DOBIVATE OVOM ANALIZOM? Detaljan i precizan izvještaj analize Vaših gena Besplatne konzultacije s našim stručnjacima, kao i s vrhunskim genetičarima iz SAD-a Status Vaših gena, savjete i uputstva koji će biti od velike pomoći Vama i Vašem liječniku prilikom određivanja najprikladnijih preventivnih mjera i eventualne terapije mybrca i mybrca HiRisk TEST: Potvrđuje Vam jeste li nosioc mutacije BRCA gena i ako jeste, koje Pomaže Vam otkriti imate li unutar obitelji članove koji se također trebaju testirati Povećava Vam izglede za rano otkrivanje i prevenciju potencijalnih oboljenja Pomaže Vašem liječniku donijeti jedinstveni plan terapije za Vas u slučaju pozitivnog nalaza TEHNIČKE INFORMACIJE Senzitivnost i specifičnost testa s analitičkim vrijednostima preko 99,99% Kliničke validacije bazirane na smjernicama koje su pod nadzorom i kontrolom nadležnih Američkih instituta za kontrolu i prevenciju bolesti Analiza gena radi se metodom sekvenciranja sljedeće generacije (NGS) na superiornim Illumina platformama Rezultate interpretira liječnik genetičar s preko 10 godina iskustva u radu NGS-om.

KOME JE mybrca TEST NAMIJENJEN? Liječnici savjetuju da bi svaka žena iznad 30 godina života trebala napraviti mybrca genetski screening test kao dio rutinske medicinske njege. Rano otkrivanje mutacija gena bitno je za prevenciju karcinoma dojke i jajnika. KOME JE mybrca HiRisk TEST NAMIJENJEN? mybrca HiRisk test preporuča se svim osobama iznad 30 godina života, kako ženama tako i muškarcima, a posebno onima koji su u grupi visokog rizika. Za Vas važno je napraviti mybrca HiRisk test ako je netko od Vaših krvnih srodnika imao jedno ili više od sljedećih oboljenja: Karcinom dojke prije 50. godine života Dva ili više primarna karcinoma dojke kod iste osobe Karcinom jajnika, karcinom jajovoda ili primarni karcinom peritoneuma Karcinom dojke kod muškarca Tri ili više od navedenih karcinoma: dojke, jajnika, jajovoda, primarnog peritoneuma, endometrija, gušterače, prostate, štitnjače, kolorektalni karcinom, sarkom, karcinom nadbubrežnih žlijezda, mozga, želuca, gastrointestinalni polipi, leukemija, melanom i karcinom bubrega Krvni srodnik s dokazanom genetskom mutacijom koja izaziva karcinom * U bliske krvne srodnike ubrajaju se prvo, drugo i treće obiteljsko koljeno

Live in the know. www.veritasgenetics.com PRISTUP VODEĆIM SVJETSKIM SPECIJALIZIRANIM KLINIKAMA Veritas Genetics je partner WorldCare International, Inc. Kao klijent Veritas Genetics-a, kada Vam je to potrebno, imate mogućnost pristupa specijalistima WorldCare Consortium bolnica koje uključuju najprestižnije institucije: Partners HealthCare System (npr. Brigham and Women's Hospital, Dana-Farber/Partners CancerCare, Massachusetts General Hospital, McLean Hospital, Spaulding Rehabilitation), Duke Medicine, Penn Medicine, kao i mogućnost kliničkog mišljenja, praćenja i konzultacija putem Veritas Genetics-ovog partnerstva s WorldCare International, Inc. OSNIVAČI VERITAS GENETICS-a Osnivači Veritas Genetics-a vodeći su svjetski stručnjaci iz područja genetike, profesori s Harvard Medical School. Među njima je i čuveni profesor George Church, 2000. godine bio je dio tima znanstvenika koji su sekvencirali ljudski genom. Partner Veritas Genetics-a za Hrvatsku Zagreb: Lovranska 8 tel: +385 1 7077 645 www.genetskitestovi.com